• SEC Filings

ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) Files An 8-K Other Events
Item 8.01 Other Events.

On December 2, 2019, Daniel J. O’Connor, President, CEO and Director of OncoSec Medical Incorporated (“OncoSec” or the “Company”), issued a letter to shareholders with a definitive proxy dated December 2, 2019 and a press release issued on December 2, 2019, regarding a strategic transaction the Company entered on October 10, 2019 with China Grand Pharmaceutical and Healthcare Holdings Limited and its U.S. affiliate, Sirtex Medical US Holdings, Inc. with respect to a $30M strategic investment at a premium to market of $2.50 per share of newly issued common stock, as well as to address certain false and /or misleading statements made by Alpha Holdings, Inc. relating to the same.

A copy of Mr. O’Connor’s letter to OncoSec shareholders is furnished as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

The following exhibit is furnished as part of this report:

ONCOSEC MEDICAL Inc Exhibit
EX-99.1 2 ex99-1.htm   OncoSec Sets the Record Straight on Alpha Holdings’ False and Misleading Statements   Strategic Investment and Partnership with CGP and Sirtex Provides an Immediate and Crucial $30 Million Cash Infusion at a Premium and Eliminates the Need to Raise Capital for the Foreseeable Future   Alpha is Attempting to Interfere with Shareholder Democracy by Suing to Prevent a Shareholder Vote on the Transaction   Alpha Offers No Viable Alternatives for OncoSec Other Than Potentially Pursuing a Highly Dilutive Financing Which Would NOT Provide Sufficient Capital   Vote “FOR” the CGP/Sirtex Transaction on the WHITE Proxy Card Today   SAN DIEGO and PENNINGTON,…
To view the full exhibit click here

About ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS)

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.